Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Savara Inc.

    NASDAQ: SVRA · Real-Time Price · USD
    3.06
    0.02 (0.66%)
    At close: Aug 18, 2025, 3:59 PM
    3.05
    -0.33%
    After-hours: Aug 18, 2025, 05:31 PM EDT
    0.66%
    Bid 2.5
    Market Cap 528.88M
    Revenue (ttm) 272K
    Net Income (ttm) -102.17M
    EPS (ttm) -0.51
    PE Ratio (ttm) -6
    Forward PE -5.75
    Analyst Buy
    Ask 3.16
    Volume 994,326
    Avg. Volume (20D) 1,641,020
    Open 3.06
    Previous Close 3.04
    Day's Range 3.01 - 3.12
    52-Week Range 1.89 - 4.70
    Beta 0.40

    About SVRA

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol SVRA
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for SVRA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts
    2 months ago
    +9.79%
    Savara shares are trading higher. Guggenheim maint... Unlock content with Pro Subscription
    2 months ago
    -31.69%
    Savara shares are trading lower after the company announced it received a refusal to file letter from the FDA for its biologics license application.
    news image

    1 day ago · businesswire.com

    Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

    LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abst...

    news image

    6 days ago · businesswire.com

    Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update

    LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second qu...

    news image

    1 month ago · businesswire.com

    Savara Announces New Employment Inducement Grant

    LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new ...

    news image

    2 months ago · accessnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

    NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Savara Inc.("Savara" or the "Company") (NASDAQ:SVRA). Such investors are advised t...

    news image

    2 months ago · accessnewswire.com

    Did Savara Inc. (SVRA) Mislead Investors? Levi & Korsinsky Investigates

    NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Savara Inc. ("Savara Inc.") (NASDAQ:SVRA) concerning possible violations o...

    news image

    2 months ago · accessnewswire.com

    SVRA ALERT: Levi & Korsinsky Investigates Savara Inc. on Behalf of Shareholders Who Lost Money

    NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Savara Inc. ("Savara Inc.") (NASDAQ:SVRA) concerning possible violations o...

    news image

    2 months ago · accessnewswire.com

    Levi & Korsinsky Launches Fraud Investigation on Behalf of Savara Inc. (SVRA) Shareholders

    NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Savara Inc. ("Savara Inc.") (NASDAQ:SVRA) concerning possible violations o...

    news image

    2 months ago · accessnewswire.com

    Savara Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

    BOSTON, MA / ACCESS Newswire / May 28, 2025 / Block & Leviton is investigating Savara Inc. (Nasdaq:SVRA) for potential securities law violations. Investors who have lost money in their Savara Inc. inv...

    news image

    2 months ago · benzinga.com

    Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?

    Savara Inc. SVRA on Tuesday announced that it received a U.S. Food And Drug Administration (FDA) refusal To File (RTF)) letter regarding the Biologic license application (BLA) for Molbreevi, a therapy...

    news image

    2 months ago · businesswire.com

    Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

    LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company received an...

    Add to Watchlist